Table 4.
Change in FEV1pp within 15–75 days and over 1 year on ivacaftor treatment according to SLC26A9 variants in patients carrying at least one G551D mutation.
| Period of evaluation | 15–75 days after ivacaftor treatment start |
Over the 1st year of ivacaftor treatment |
||||
|---|---|---|---|---|---|---|
| SLC26A9 variants$ | G551D/other (n = 14) |
G551D/other (n = 16) |
||||
| SNP | FEV1pp change∗ | P-value | Adjusted P-value∗∗ | FEV1pp change∗ | P-value | Adjusted P-value∗∗ |
| rs7512462 | –7.7 ± 1.7 | 0.0007 | 0.0049 | –7.8 ± 2.4 | 0.0063 | 0.0441 |
| rs1874361 | 4.4 ± 1.5 | 0.0107 | 0.0749 | 3.1 ± 3.0 | 0.3129 | 1.0000 |
| rs12741299 | 2.9 ± 6.0 | 0.6336 | 1.0000 | 2.1 ± 5.9 | 0.7331 | 1.0000 |
| rs4077468 | –7.9 ± 1.3 | 0.0001 | 0.0007 | –8.4 ± 1.7 | 0.0003 | 0.0027 |
| rs4077469 | –9.3 ± 1.9 | 0.0005 | 0.0035 | –10.5 ± 2.3 | 0.0006 | 0.0042 |
| rs12047830 | –10.9 ± 2.7 | 0.0020 | 0.014 | –7.5 ± 3.5 | 0.0518 | 0.3626 |
| rs7419153 | 9.8 ± 2.1 | 0.0007 | 0.0049 | 8.1 ± 2.6 | 0.0089 | 0.0623 |
$See description Supplementary Table S2; ∗linear regression of FEV1pp (forced expiratory volume in 1 s percent-predicted) change with additive model adjusted on baseline; ∗∗Bonferroni adjustment.